What Happened?
Shares of medical technology company Inspire Medical Systems (NYSE:INSP) jumped 7.4% in the morning session after Stifel analyst Jonathan Block raised the price target on the company to $80.00 from $75.00 while maintaining a Buy rating.
The upward revision in the price target reflects sustained positive sentiment from the research firm regarding the company. A price target increase indicates an analyst's expectation of further stock price appreciation, while maintaining a Buy rating highlights continued confidence in the company's operational performance and long-term trajectory. Positive commentary and price target adjustments from Wall Street analysts often boost investor sentiment and drive buying interest in the market.
After the initial pop, the shares cooled down to $70.71, up 3.8% from the previous close.
Is now the time to buy Inspire Medical Systems? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Inspire Medical Systems’s shares are extremely volatile and have had 30 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 10 months ago when the stock gained 28.6% on the news that the Centers for Medicare & Medicaid Services (CMS) finalized a rule significantly increasing payment rates for the company's sleep apnea procedures. Starting in 2026, hospitals and surgical centers will receive approximately $10,000 more per procedure compared to current rates. This regulatory win is a massive catalyst for Inspire because Medicare accounts for roughly 25-30% of its patient mix. The increased reimbursement provides a strong financial incentive for hospitals to prioritize these surgeries, which should drive higher procedure volumes. Reacting to the news, Stifel upgraded the stock from "Hold" to "Buy" with a new price target of $110. Analysts noted that the company's previous struggles are turning into opportunities. Specifically, they believe that "patient warehousing", where surgeries were delayed in anticipation of better rates, will likely result in a surge of volume in 2026. With advertising spend also ramping back up, the outlook for the medical device maker has improved substantially. Contributing to the positive news, healthcare stocks surged after a Politico report revealed the White House plans to pitch a two-year extension of Obamacare subsidies. The proposal would extend subsidies set to expire at the end of the year, with new eligibility limits for individuals with incomes up to 700% of the federal poverty line. These subsidies, a key part of the Affordable Care Act (ACA), help lower the cost of health insurance for consumers. An extension would likely support sustained enrollment, improving the demand and growth forecasts for healthcare companies.
Inspire Medical Systems is down 23.4% since the beginning of the year, and at $70.71 per share, it is trading 50.9% below its 52-week high of $143.99 from December 2025. Investors who bought $1,000 worth of Inspire Medical Systems’s shares 5 years ago would now be looking at only $301.21.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.